卡维地洛治疗慢性心力衰竭的临床观察

Clinical observation of curative effect of carvedilol in patients with chronic heart failure

目的:探讨卡维地洛对慢性心力衰竭患者心功能的疗效和安全性。方法:将51例慢性心力衰竭患者随机分为两组,卡维地洛组26例,对照组25例。两组患者基础临床特征相似,应用彩色超声心动图测量患者治疗前、后6个月射血分数(LVEF)及左心室腔径变化,并观察患者的NYHA心功能分级、血压、心率(律)的变化。结果:6个月后,卡维地洛组的LVEF比对照组明显升高[LVEF:(46.52±6.24)%比(39.62±5.63)%],P<0.05,左室舒张末径(LVDd)和收缩末径(LVDs)均比对照组明显下降[LVDd:(52.24±6.12)mm比(58.34±6.31)mm;LVSd:(39.35±5.31)mm比(43.71±5.64)mm],P<0.05。治疗6个月后卡维地洛组患者的NYHA心功能分级改善优于对照组。结论:卡维地洛对慢性心力衰竭的治疗是有效和安全的。

Objective:To explore the efficacy and safety of carvedilol in patients with chronic heart failure.Methods:51cases of chronic heart failure were divided into two groups,namely carvedilol group(26cases)and control group(25cases).Their basic clinical characteristics were similar.LVEF and change of left ventricular diameter before and after6months of treatment were measured by color ultrasonographocardigram,and the alterations of NYHA cardiac function scale,blood pressure and heart rate were also observed simultaneously.Results:Compared with the control group after6months of treatment,LVEF of carveidilol group was significantly increased(46.52±6.24%vs39.62±5.63%,P<0.05),both LVDd and LVDs were significantly shortened(LVDd:52.24±6.12mm vs58.34±6.31mm,LVDs:39.35±5.31mm vs43.71±5.64mm,all P<0.05).The improvement of NYHA cardiac function scale in the carvedilol group after6months of treatment was superior to that in the control group.Conclusion:Patients with chronic heart failure treated with carvedilol is effective and safe.